the Rest Peptide Mechanism Weight Loss Potential Typical Use Cagrilintide Amylin analog Moderate to high (especially in combo) Weight loss adjunct Semaglutide GLP-1 agonist High Obesity, type 2 diabetes Tirzepatide GIP/GLP-1 dual agonist Very high Obesity, type 2 diabetes Retatrutide GIP/GLP-1/Glucagon triple agonist Extremely high (research stage) Experimental weight loss agent Future of Cagrilintide and Its Dosage Schedules As the body of research grows, Cagrilintide dosage schedules will likely become more refined based on user response and clinical trials
Semaglutide oral drops* are a non-injectable formulation of semaglutide, delivering the same active compound under the tongue instead of via injection
Similar effects were seen with liraglutide, the active ingredient in the weight loss drug Saxenda, and the diabetes drug Victoza
Moreover, the once-weekly dosing option improves patient compliance compared to daily injections or multiple daily oral medications, marking a significant advancement in diabetes treatment
We understand that even minute impurities can compromise an entire study, leading to skewed data and wasted resources
In addition, some outcomes as NAION appear to be driven by a limited number of studies, reducing the robustness of the estimates